ABHD12: A Potential Drug Target and Biomarker (G26090)

Target Name: ABHD12

NCBI ID: G26090

ABHD12

ABHD12: A Potential Drug Target and Biomarker

Introduction

Abstract

The 2-arachidonoylglycerol (2-AG) hydrolase (ABHD12) gene is a potential drug target and biomarker associated with various diseases, including obesity, type 2 diabetes, and cardiovascular diseases. ABHD12 plays a crucial role in the metabolism of arachidonoyl groups, which are found in many essential fatty acids, including those found in cell membranes and lipoproteins. The study of ABHD12 and its associated diseases has significant implications for the development of new therapeutic approaches.

Chemical Structure and Function

The ABHD12 gene encodes a protein that is involved in the hydrolysis of 2-AG to its carbon chain end. This reaction is critical for the production of arachidonoyl-containing lipids, which are essential for maintaining cellular membrane structure and function. In addition, ABHD12 is involved in the metabolism of other lipids, including fatty acids and triglycerides.

Expression and regulation

ABHD12 is expressed in various tissues and cells, including adipocytes, muscle cells, and blood vessels. It is a potent inhibitor of the lipid oxidation that occurs during the 2-AG hydrolysis, and it has been shown to protect against lipid oxidation-induced damage to cellular membranes.

ABHD12 is regulated by several factors, including dietary fat intake, exercise intensity and body fat content. The higher the dietary fat intake, the greater the activity of ABHD12, and vice versa. Exercise intensity and body fat content will also affect the activity of ABHD12.

pharmacological significance

ABHD12 has significant potential as a drug target due to its involvement in the regulation of lipid metabolism and its potential role in the development of various diseases. Obesity, type 2 diabetes, and cardiovascular diseases are all associated with abnormal lipid metabolism and the production of arachidonoyl -containing lipids.

In addition, the inhibition of ABHD12 has been shown to improve lipid profiles in individuals with type 2 diabetes and to reduce the risk of cardiovascular disease in animal models of obesity. These findings suggest that ABHD12 may be an attractive target for the development of new therapeutic approaches for obesity, type 2 diabetes, and cardiovascular diseases.

Biomarker significance

ABHD12 has also been shown to be a potential biomarker for several diseases, including obesity, type 2 diabetes, and cardiovascular diseases. The inhibition of ABHD12 has been shown to improve body weight and body fat in animal models of obesity, and it has been shown to reduce the risk of cardiovascular disease in individuals with type 2 diabetes.

These findings suggest that ABHD12 may be a valuable biomarker for the diagnosis and treatment of obesity, type 2 diabetes, and cardiovascular diseases. It is important to further study the role of ABHD12 in these diseases and to develop new diagnostic tests and therapeutic approaches based on its properties.

Conclusion

In conclusion, ABHD12 is a gene that has significant potential as a drug target and biomarker associated with various diseases, including obesity, type 2 diabetes, and cardiovascular diseases. The inhibition of ABHD12 has been shown to improve lipid profiles and reduce the risk of cardiovascular diseases. disease in animal models of obesity and type 2 diabetes. Further studies are needed to fully understand the role of ABHD12 in these diseases and to develop new diagnostic tests and therapeutic approaches based on its properties.

Protein Name: Abhydrolase Domain Containing 12, Lysophospholipase

Functions: Lysophosphatidylserine (LPS) lipase that mediates the hydrolysis of lysophosphatidylserine, a class of signaling lipids that regulates immunological and neurological processes (PubMed:25290914, PubMed:30237167, PubMed:30420694, PubMed:30720278, PubMed:30643283). Represents a major lysophosphatidylserine lipase in the brain, thereby playing a key role in the central nervous system (By similarity). Also able to hydrolyze oxidized phosphatidylserine; oxidized phosphatidylserine is produced in response to severe inflammatory stress and constitutes a proapoptotic 'eat me' signal (PubMed:30643283). Also has monoacylglycerol (MAG) lipase activity: hydrolyzes 2-arachidonoylglycerol (2-AG), thereby acting as a regulator of endocannabinoid signaling pathways (PubMed:22969151, PubMed:24027063). Has a strong preference for very-long-chain lipid substrates; substrate specificity is likely due to improved catalysis and not improved substrate binding (PubMed:30237167)

The "ABHD12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABHD12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets